Department of Pharmacy Practice, University of Kansas School of Pharmacy, Kansas City, KS, USA; Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical Center, Kansas City, KS, USA.
Department of Pharmacy Practice, University of Kansas School of Pharmacy, Kansas City, KS, USA.
J Clin Lipidol. 2019 Jan-Feb;13(1):170-175. doi: 10.1016/j.jacl.2018.11.005. Epub 2018 Nov 15.
Dietary fish oil supplements containing the omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are frequently used for cardiovascular benefit. However, several factors may limit the intake of prescribed doses.
The objective of this study is to compare the prescribed, patient self-reported, and actual intake of supplemental EPA + DHA doses in a lipid-specialty clinic and identify common barriers and influences to therapy.
Seventy-six patients prescribed supplemental fish oil were randomly selected to participate in a 28-item cross-sectional survey for evaluating patient knowledge and intake of prescribed supplemental EPA + DHA doses. Self-reported data were collected during a follow-up clinic visit, whereas actual intake was determined when patients had access to their fish oil bottle. These data were compared with their chart-documented prescribed EPA + DHA dose.
Many patients were well-educated and had attended the lipid-specialty clinic for approximately 2 years but only 28.9% were confident that they could accurately recall their daily EPA + DHA dose. There were statistically significant differences between the prescribed doses and patients' self-reported doses (3600 mg vs 2750 mg, P = .014), as well as between prescribed doses and actual intake (3600 mg vs 1575 mg, P < .001). Patients reported multiple barriers and influences to explain their use of fish oil products.
Most patients using supplemental fish oil in a lipid-specialty clinic were not taking the prescribed amount of EPA + DHA, with many using markedly lower than prescribed doses. This is likely because of several factors including the complexities of supplemental fish oil doses and labeling, product availability, and discount sales. These findings suggest that supplemental fish oil requires continuous education and dosing guidance.
含有ω-3 多不饱和脂肪酸，二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的饮食鱼油补充剂常用于心血管益处。然而，有几个因素可能会限制规定剂量的摄入。
本研究的目的是比较脂质专科诊所中规定的、患者自我报告的和实际补充 EPA+DHA 剂量的摄入量，并确定治疗的常见障碍和影响因素。
随机选择 76 名服用补充鱼油的患者参加了一项 28 项的横断面调查，以评估患者对规定补充 EPA+DHA 剂量的知识和摄入量。自我报告的数据是在随访就诊时收集的，而实际摄入量是在患者可以使用鱼油瓶时确定的。将这些数据与他们图表记录的规定 EPA+DHA 剂量进行比较。
许多患者受过良好的教育，并且已经参加了脂质专科诊所大约 2 年，但只有 28.9%的患者有信心能够准确回忆起他们的每日 EPA+DHA 剂量。规定剂量与患者自我报告的剂量之间存在统计学显著差异（3600mg 与 2750mg，P=0.014），以及规定剂量与实际摄入量之间的差异（3600mg 与 1575mg，P<0.001）。患者报告了多种障碍和影响因素来解释他们使用鱼油产品的情况。
大多数在脂质专科诊所使用补充鱼油的患者没有服用规定量的 EPA+DHA，许多人服用的剂量明显低于规定剂量。这可能是由于多种因素造成的，包括补充鱼油剂量和标签的复杂性、产品的可获得性和折扣销售。这些发现表明，补充鱼油需要持续的教育和剂量指导。
